AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$MIRM

Peetz Christopher sold $3.0M of MIRM

Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 30,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $98.68 ($98.08–$98.91, $2.96M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Peetz Christopher
Published Sep 3, 2026, 10:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MIRM
Neutral
medium confidence
Mentioned
$MIRM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MIRMNeutralLow
01

Why it matters

The disclosed sale is the first public report of this insider transaction, providing new data for valuation models.

02

Market read

Insider sale adds modest negative sentiment but unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data releases or financing events not disclosed may contextualize the sale.

Relevance 5/10Novelty 6/10Timing: post‑market Sep 1, 2026

Background

Form 4 filing discloses insider transactions; investors monitor for signals.

Company-level read

Ticker impact

$MIRMNeutralMedium confidence
Context

CEO Christopher Peetz sold ~30,000 shares for $2.96M via a 10b5-1 plan on Sep 1, 2026.

Expected impact

Potential short-term downward pressure, likely limited to a few percent.

Evidence & confidence

Sale represents ~15% of post‑transaction holdings; market may view as routine 10b5‑1 execution.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common and not sector‑wide signal.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global relevance; only affects Mirum shareholders.

Counterpoint

What could challenge this read

Sale could be a strategic liquidity move unrelated to company outlook; price may stay stable.

Key entities

  • Company
    Mirum Pharmaceuticals, Inc.

    Biotech firm developing treatments for liver disease.

  • Executive
    Christopher Peetz

    Chief Executive Officer of Mirum.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MIRM insider trading history →

Related articles

NOV 2
$MIRMHighAI 8/10

Mirum will present longer-term hepatitis D response data, including in people with cirrhosis.

Mirum Pharmaceuticals will present data on its hepatitis D treatment, brelovitug, at The Liver Meeting 2026, including Phase 3 results and longer-term efficacy in patients with cirrhosis. The company will also share additional analyses on volixibat for primary sclerosing cholangitis (PSC) and new evidence on LIVMARLI (maralixibat) for rare cholestatic liver diseases.

stocktitan.net3 min
OCT 26
$MIRMMedAI 8/10

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) reported positive results from Cohort 2 of the PROGRESS study for ATEBRIOZ (zilurgisertib) in pediatric FOP patients aged 6 to <12. The drug reduced HO lesion volume and improved joint mobility, with no new lesions. Mirum plans an sNDA submission in H1 2027 to expand the indication. Safety findings were consistent with prior data.

financialcontent.com2 min
OCT 26
$MIRMHighAI 9/10

Mirum Pharmaceuticals Reports Positive Pediatric ATEBRIOZ Study Results

Mirum Pharmaceuticals reported positive results from a pediatric study of ATEBRIOZ, showing reduced heterotopic ossification and improved joint mobility in children aged 6 to under 12 with FOP. At Week 24, lesion volume decreased by 8.09 cm³ with zilurgisertib and increased by 9.14 cm³ with placebo. The company plans to submit an sNDA in the first half of 2027 for expanded use.

tradingview.com1 min
OCT 26
$MIRMMedAI 9/10

Mirum Pharmaceuticals, Inc. (MIRM): Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with…

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On October 26, 2026, Mirum Pharmaceuticals, Inc. (the “Company”)

SEC EDGAR 8-K2 min